Latest Covid-19 shots are almost ready: Why is the US authorizing a different booster than the rest of the world?
The US FDA later this week will authorize the latest weapon in the ever-shifting battle against Covid-19, setting up another national campaign to get the free shots into arms ahead of winter.
But the decision comes with some drama (as each of the prior authorizations has) because this newest booster is not only the first bivalent vaccine for Covid in the US, but also arrives without human data, and it’s a different booster from what other high-income countries are authorizing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.